Abstract: An antibiotic R106 represented by the general formula (I): ##STR1## wherein: R is methyl or ethyl;X.sub.1 is MePhe, .beta.-HOMePhe or Phe;X.sub.2 is allo-Ile, Val or Leu;X.sub.3 is MeVal or Val;X.sub.4 is .beta.-HOMeVal, .gamma.-HOMeVal, MeVal, Val, N,.beta.-MeAsp, .beta.-HOMePhe, MePhe, MeDH.sub.2,3 Val or MeDH.sub.3,4 Valis produced by a process which comprises culturing a strain of the genus Aureobasidium that is capable of producing the said antibiotic R106 and collecting the said antibiotic from the fermentation broth. The antibiotic R106 compounds are useful in the treatment of fungal infection.

Abstract: Molecular sieve compositions having three-dimensional microporous framework structures of BO.sub.2, AlO.sub.2, PO.sub.2 and SiO.sub.2 tetrahedral oxide units are disclosed. These molecular sieves have an empirical chemical composition on an anhydrous basis expressed by the formula:mR:(B.sub.w Al.sub.x P.sub.y Si.sub.z)O.sub.2wherein "R" represents at least one organic templating agent present in the intracrystalline port system; "m" represents the molar amount of "R" present per mole of (B.sub.w Al.sub.x P.sub.y Si.sub.z)O.sub.2 ; and "w", "x", "y" and "z" represent the mole fraction of boron, aluminum, phosphorus and silicon, respectively, present as tetrahedral oxides. Their use as adsorbents, catalysts, etc. is also disclosed.

Abstract: Process for the production of anhydrous calcium fluosilicate from anhydrous calcium chloride and impure fluosilicic acid solution, a by-product of the acid treatment of phosphorus ores containing fluorine, characterized in that a calcium fluosilicate dihydrate is precipitated at low temperature and quantitatively by suitable adjustment of the fluosilicic acid concentration and the molar ratio CaCl.sub.2 /H.sub.2 SiF.sub.6 and that after filtration, washing and drying of the precipitate, an anhydrous calcium fluosilicate which can be easily decomposed by heat treatment is obtained to restore calcium fluoride and silicon tetrafluoride suitable for the manufacture of pure hydrofluoric acid and fluosilicic acid.For gravimetric concentrations of H.sub.2 SiF.sub.6 >25% and molar concentration ratios CaCl.sub.2 /H.sub.2 SiF.sub.6 between 2 and 5, the yields of the anhydrous calcium fluosilicate obtained are greater than 94%.

Abstract: Compounds acting as antagonists of the antidiuretic/and or vasopressor activity of arginine vasopressin are those of the formulaA--CH.sub.2 CO--D--Tyr(R)--Phe--Y--Asn--T--U--Z--Qwherein A is a-adamantyl, cyclohexyl, cyclopentyl, 1-mercaptocyclohexyl, 1-mercaptocyclopentyl, 1-ethyl-1-mercaptopropyl, yclohexylmethyl, cyclopentylmethyl, methyl, isopropyl, tert-butyl or phenyl; R is alkyl of 1-4 carbon atoms; Y is Val, Ile, Thr, Ala, Lys, Cha, Nva, Met, Nle, Orn, Ser, Asn, Gln, Phe, Tyr, Gly, Abu or Leu; T is Pen, Abu, Orn, Oys, Arg, Ala, Cha or Thr; U is Pro, Arg, Lys or Orn or a single bond; Z is (d-or L-) Arg, Orn or Lys and Q is Gly(NH.sub.2), Arg (NH.sub.2), Orn(NH.sub.2), Lys (NH.sub.2), (D- or L-)Ala(NH.sub.2), Ser(NH.sub.2), Val(NH.sub.2), Phe(NH.sub.2), Ile(NH.sub.2), Thr(NH.sub.2), Pro(NH.sub.2), Tyr(NH.sub.2), NH.sub.2, OH, NHR, NGbzl, NH(CH.sub.2).sub.p NH.sub.2 or NH(CH.sub.2).sub.p OH, wherein R is as above and p is an integer from 2 to 6. Compounds wherein T is Cys have similar activity.

Abstract: Cyclosporins are useful immunosuppressive, anti-fungal and antiphlogistic agents which are relatively insoluble in water and aqueous fluids (including body fluids). They may be rendered more soluble by the concomitant administration of .alpha.-cyclodextrin, either separately, but essentially simultaneously or, preferably, in admixture.

Abstract: Tripeptides having hypotensive activity, defined by the following general formula:A--B--C--OZ (I)wherein:A represents a residue of L-pyroglutamic acid, L-proline of L-proline bearing a substituent on its amino group ##STR1## wherein R.sub.1 is an acyl with a number of carbon atoms in straight chain not higher than 9, a benzyloxycarbonyl group or an alkyloxycarbonyl group;B is an .alpha.-aminoacide residue derived from one of the natural aminoacids;C is a residue of L-tryptophan (Trp), of L-phenylalanine (Phe) or of L-tyrosine (Tyr);Z is a hydrogen atom or an alkyl group with a number of carbon atoms in straight chain not higher than 9.

Abstract: Novel and improved antibody compositions comprising an antibody or antibody fragment having an increased number of sites on a carbohydrate side chain available for the site specific attachment of a compound to a region of the antibody or antibody fragment which is not part of nor directly involved with the antigen binding site are disclosed. Conjugates, prepared using the high-mannose-containing antibodies, which are characterized by substantially the same immunospecificity as the unmodified unconjugated antibody molecule, are also disclosed. The antibody compositions are advantageously used for a wide variety of therapeutic and diagnostic applications in both in vivo and in vitro targeted delivery systems and assays. Methods for preparing the antibody compositions, as well as antibody conjugate intermediates, and methods for using the antibody compositions are also described.

Abstract: A new group of cyclic peptides, the A54145 cyclic peptides, which have the general formula: ##STR1## wherein: R is selected from the group consisting of hydrogen, an amino-protecting group, 8-methylnonanoyl, 8-methyldecanoyl and n-decanoyl;(Lys-R.sup.1) represents --NH(CH.sub.2).sub.4 CH(NHR.sup.1)CO--;R.sup.1 is hydrogen or an amino-protecting group;X is Ile or Val: andY is Glu or 3-MG; provided that R.sup.1 cannot be hydrogen when R is 8-methylnonanoyl, 8-methyldecanoyl or n-decanoyl;and their salts are useful intermediates in the preparation of anitbacterial agents.

Abstract: A method for preventing conception in mammals which includes administering to the mammals a composition containing (1) free LHRH or its analog and (2) an immunogenic conjugate between LHRH or its analog and a carrier protein. Free LHRH or its analog acts to prevent conception in the mammal during the period from administration to about 6 weeks; the immunogenic conjugate acts to prevent conception during the period from about 6 weeks after administration until the LHRH antibodies formed in response to the conjugate are metabolized, generally about 0.5-2 years.

Abstract: An antimicrobial composition for the treatment of non-oral and non-periodontal human disorders due to infectious microorganisms susceptible to antimicrobial treatment and wherein the composition is an aqueous or aqueous alcoholic solution of povidone iodine complex to which nascent oxygen is supplied and the resulting admixture being freshly applied to the said disorders.

Abstract: An antibacterial substance comprising a peptide comprising a fragment constituting lepidopteran A and containing the N-terminal amino acid residue of the lepidopteran A, wherein the carboxyl group at the C-terminal of said peptide is substituted with an alkyl amide group represented by Formula (I):--CONH(CH.sub.2).sub.n CH.sub.3 (I)wherein n is an integer of 2 to 16.This antibacterial substance shows good antibacterial activities against various bacteria, and is useful as pharmaceuticals and agricultural chemicals.

Abstract: The bitter taste of ranitidine may be masked by forming an adsorbate with a synthetic cation exchange resin. The adsorbate is particularly suitable for use in pharmaceutical compositions for oral administration such as chewable or suckable tablets, granules and aqueous or non-aqueous suspensions.

Abstract: A pheromone biosynthesis activating neuropeptide (Hez-PBAN) hormone, controlling sex pheromone production in moths and controlling melanizing in larvae, was isolated from the brain-suboesophageal ganglion complexes of adult corn earworm Heliothis zea. Hez-PBAN has 33 amino acide residues and a molecular weight of 3900; its amino acid sequence is unique among the fully characterized peptide hormones. Synthetic PBAN and related structures induced production of sex pheromone in ligated H. zea females and other moth species and melanization in larvae that resulted in morphological changes or death.

Abstract: Cytotoxic antibody conjugates in which a folic acid-antagonistic folic acid analogue is bound to an antibody or its fragment through an oligopeptide. The conjugates can be used as a chemotherapeutic agent against malignant tumors.

Abstract: A new group of cyclic peptide derivatives, the A54145 cyclic peptide derivatives, which have the general formula: ##STR1## wherein: R is C.sub.8 -C.sub.18 -alkyl, optionally substituted C.sub.8 -C.sub.18 -alkanoyl or C.sub.8 -C.sub.18 -alkenoyl;(R,R.sup.2)-Trp represents a group of formula ##STR2## (Lys-R.sup.1) represents --NH(CH.sub.2).sub.4 CH(NHR.sup.1)CO--; R.sup.1 is hydrogen or an amino-protecting group; andR.sup.2 is hydrogen; orR and R.sup.2, taken together, represent a C.sub.8 -C.sub.18 -alkylidene group;X is Ile or Val; andY is Glu or 3-MG;provided that: 1) when R.sup.1 =H, X=Ile and Y=Glu or 3-MG, R cannot be 8-methylnonanoyl, 8-methyldecanoyl or n-decanoyl; 2) when R.sup.1 =H, X=Val and Y=3-MG, R cannot be 8-methyldecanoyl; and 3) when R.sup.1 =H, X=Val and Y=Glu, R cannot be 8-methylnonanoyl; and 4) when R.sup.1 is an amino protecting group, R cannot be 8-methylnonanoyl, 8-methyldecanoyl, or n-decanoyl; and their salts are antibacterial agents or intermediates to such agents.

Abstract: Provided are microbiocidal solutions comprising an aryl alkanol solvent and a microbiocidal compound dissolved therein. The solutions may be used to impart microbiocidal properties to polymer compositions.

Abstract: This invention relates to synergistic biocide compositions having decreased sensitization potential.

Abstract: Conjugate immunogens are disclosed, comprising peptide fragments having substantial homology to the N-terminal region of Pasteurella haemolytica leukotoxins, covalently linked to suitable carrier proteins.

Abstract: According to the present invention oil-free vaccines are provided which contain polyoxypropylenepolyoxyethylene polyols as well as an acrylic acid polymer as adjuvating constituents. These vaccines were found to show excellent immunizing properties.

Abstract: Human Growth Hormone-Releasing Factor (hGRF) analogs having the sequence [X.sup.3, Y.sup.8, Z.sup.25, Nle.sup.27 ]-hGRF(1-A)--B, wherein X, Y and Z are selected from the group consisting of Asn and Asp, A has a value from 29-44, and B is NH.sub.2 or OH are synthesized and administered to animals to stimulate the release of Growth Hormone (GH).